A recent study revealed that silencing Xist attenuated AD-associated BACE1 alterations via the miR-124/BACE1 signaling pathway [29], which encourages speculation that Xist is a potential target for the treatment of AD. This evidence concerns the gene BACE1 and Alzheimer disease.